Meta-Analysis Shows Survival Benefit of Preoperative Chemotherapy in NSCLC

Among the articles most read on, January–April 2014

Get Permission

In a systematic review and individual patient meta-analysis reported in The Lancet,1 the NSCLC Meta-analysis Collaborative Group found that neoadjuvant therapy for non–small cell lung cancer (NSCLC) was associated with a significant 13% reduction in risk of death. Significant benefits in recurrence-free survival and time to distant recurrence were also observed.1

Preoperative chemotherapy was associated with a 13% improvement in overall survival. Preoperative chemotherapy was associated with a 15% improvement in recurrence-free survival and a 31% improvement in time to distant recurrence.

The investigators concluded, “Findings, which are based on 92% of all patients who were randomised, and mainly stage IB–IIIA, show preoperative chemotherapy significantly improves overall survival, time to distant recurrence, and recurrence-free survival in resectable NSCLC. The findings suggest this is a valid treatment option for most of these patients. Toxic effects could not be assessed.”

For full disclosures of the study authors, visit ■


1. NSCLC Meta-analysis Collaborative Group: Preoperative chemotherapy for non-small cell lung cancer. Lancet. February 25, 2014 (early release online).

For the full ASCO Post report, click here.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.